title: Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer.
abstract: Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive factors has the potential to improve outcome in NSCLC. This review focuses on the most important molecular prognostic and/or predictive factors in the treatment of advanced NSCLC; considering these molecular features, we also suggest a molecular-based treatment algorithm.
authors.affiliation: Division of Medical Oncology, Centro di Riferimento Oncologico di Basilicata, IRCCS, Via Padre Pio 1, 85028 Rionero in Vulture, PZ, Italy. tarta1@virgilio.it
authors.forename: Alfredo
authors.initials: A
authors.lastname: Tartarone
authors.forename: Rose
authors.initials: R
authors.lastname: Lerose
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Gallucci
authors.forename: Raffaele
authors.initials: R
authors.lastname: Ardito
authors.forename: Michele
authors.initials: M
authors.lastname: Aieta
mesh_terms: D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000379:methods*; D011379:Prognosis